Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by Amalfi1on May 08, 2019 10:16am
90 Views
Post# 29724113

RE:RE:RE:volume today

RE:RE:RE:volume todayIf you think this company is so bad and overvalued... why are you still an investor in it?  I love what you are doing though....trying to get the investors to listen to you, panic and sell.  You will then buy some cheap shares, and wait for the inevitable rise in the share price.  Jay is no slouch, he just doesn’t understand the promotions part of a public company.  That is why he smartly hired the new PR person (Judy Ann).  She seems to be agressive, and I hope she gets the investment community to finally see this undervalued company.  VIR has all the sales licenses except one. (I think it doesn’t have the sales license for oils).  News announcement this morning says they have sold Clones to one of the first micro cultivators.  That is a big PLUS, as I know the big boys are trying to secure the micros to sell to them.  Funny that one of the first micro growers decided to do the deal with VIR instead of one of the big boys.  The AGM is soon.  
<< Previous
Bullboard Posts
Next >>